BLAINJECTIONINJECTABLE
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
MVASI (bevacizumab-awwb) by Amgen is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2017.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MVASI (bevacizumab-awwb) is a monoclonal antibody biosimilar to Avastin that inhibits vascular endothelial growth factor (VEGF) to prevent tumor angiogenesis. It is approved as a biosimilar referencing the originator bevacizumab and is used across multiple cancer indications including colorectal, lung, breast, and ovarian cancers. The drug works by blocking VEGF signaling, thereby reducing blood vessel formation that tumors depend on for growth.
$13.0MPart D
PeakStable
approximately 8% of bevacizumab biosimilar segment
MVASI is in peak commercial phase with modest spending; Amgen team is focused on maintaining biosimilar share against established competitors rather than driving rapid growth.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Started Jul 2024
450 enrolled
Metastatic Colorectal Cancer
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Started Jun 2022
0Non Small Cell Lung Cancer
Career Relevance
MVASI offers careers focused on biosimilar market access, formulary defense, and price-based competition rather than innovation-driven launch activities. Working on this product develops expertise in biosimilar dynamics, payer negotiations, and mature-market competition—valuable skills in the increasingly biosimilar-saturated oncology space.
Worked on MVASI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.